 | Up a level |
Journal Article
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A. D., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann. Oncol., 29. S. 175 - 176. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Paz-Ares, L., Doebel, R. C., Farago, A. F., Liu, S., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Ye, C., Simmons, B. and Demetri, G. D. (2020). Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK-fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 74. S. S128 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790